Total Payments
$8,717
2024 Payments
$346.56
Companies
18
Transactions
47
Medicare Patients
3,586
Medicare Billing
$1.4M
Payment Breakdown by Category
Consulting$4,365 (50.1%)
Travel$2,178 (25.0%)
Food & Beverage$1,320 (15.1%)
Research$653.45 (7.5%)
Education$201.14 (2.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $4,365 | 1 | 50.1% |
| Travel and Lodging | $2,178 | 7 | 25.0% |
| Food and Beverage | $1,320 | 30 | 15.1% |
| Unspecified | $653.45 | 1 | 7.5% |
| Education | $201.14 | 8 | 2.3% |
Payments by Type
General
$8,064
46 transactions
Research
$653.45
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Daiichi Sankyo Inc. | $5,009 | 6 | $0 (2019) |
| Exelixis Inc. | $2,177 | 13 | $0 (2024) |
| Eli Lilly and Company | $653.45 | 1 | $0 (2023) |
| Aveo Pharmaceuticals, Inc. | $160.98 | 2 | $0 (2024) |
| Cardinal Health 110 LLC | $137.20 | 2 | $0 (2021) |
| Eisai Inc. | $124.69 | 2 | $0 (2024) |
| Merck Sharp & Dohme LLC | $102.62 | 1 | $0 (2023) |
| Janssen Biotech, Inc. | $58.83 | 2 | $0 (2024) |
| PFIZER INC. | $49.61 | 6 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $47.91 | 2 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $346.56 | 13 | Aveo Pharmaceuticals, Inc. ($99.99) |
| 2023 | $3,021 | 20 | Exelixis Inc. ($2,160) |
| 2022 | $182.60 | 3 | EISAI INC. ($100.31) |
| 2021 | $149.12 | 3 | Cardinal Health 110 LLC ($137.20) |
| 2019 | $5,009 | 6 | Daiichi Sankyo Inc. ($5,009) |
| 2018 | $1.14 | 1 | PFIZER INC. ($1.14) |
| 2017 | $8.12 | 1 | PFIZER INC. ($8.12) |
All Payment Transactions
47 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/25/2024 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $36.36 | General |
| Category: Oncology | ||||||
| 11/04/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $17.44 | General |
| Category: Oncology | ||||||
| 09/16/2024 | Telix Pharmaceuticals | ILLUCCIX (Drug), ILLUCCIX | Food and Beverage | In-kind items and services | $22.91 | General |
| Category: PROSTATE CANCER DIAGNOSIS | ||||||
| 09/09/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Food and Beverage | In-kind items and services | $23.74 | General |
| Category: ONCOLOGY | ||||||
| 08/20/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $18.09 | General |
| Category: Oncology | ||||||
| 08/06/2024 | PFIZER INC. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $21.37 | General |
| Category: Oncology | ||||||
| 07/13/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $17.93 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 06/11/2024 | PFIZER INC. | TALZENNA (Drug), XTANDI | Education | In-kind items and services | $3.78 | General |
| Category: ONCOLOGY | ||||||
| 06/03/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $24.38 | General |
| Category: Oncology | ||||||
| 05/30/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $18.90 | General |
| Category: Oncology | ||||||
| 05/10/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Education | In-kind items and services | $99.99 | General |
| Category: Oncology | ||||||
| 04/29/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Food and Beverage | In-kind items and services | $24.17 | General |
| Category: ONCOLOGY | ||||||
| 01/31/2024 | TerSera Therapeutics LLC | Xermelo (Drug) | Food and Beverage | In-kind items and services | $17.50 | General |
| Category: Oncology | ||||||
| 11/14/2023 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $22.47 | General |
| Category: Oncology | ||||||
| 10/31/2023 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Food and Beverage | In-kind items and services | $17.04 | General |
| Category: ONCOLOGY | ||||||
| 10/24/2023 | TerSera Therapeutics LLC | Zoladex (Drug) | Food and Beverage | In-kind items and services | $24.01 | General |
| Category: Oncology | ||||||
| 08/21/2023 | Amgen Inc. | Blincyto (Biological), Kyprolis | Food and Beverage | In-kind items and services | $26.79 | General |
| Category: Oncology | ||||||
| 06/26/2023 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | Cash or cash equivalent | $1.38 | General |
| Category: Oncology | ||||||
| 06/23/2023 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | Cash or cash equivalent | $19.64 | General |
| Category: Oncology | ||||||
| 05/24/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $102.62 | General |
| Category: ONCOLOGY | ||||||
| 05/08/2023 | Eli Lilly and Company | — | — | In-kind items and services | $653.45 | Research |
| Study: EMBER-4: A RANDOMIZED OPEN-LABEL PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+ HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE | ||||||
| 03/22/2023 | PFIZER INC. | INLYTA (Drug) | Education | In-kind items and services | $7.60 | General |
| Category: ONCOLOGY | ||||||
| 01/31/2023 | PFIZER INC. | INLYTA (Drug) | Education | In-kind items and services | $7.60 | General |
| Category: ONCOLOGY | ||||||
| 01/11/2023 | Exelixis Inc. | — | Travel and Lodging | In-kind items and services | $376.35 | General |
| 01/11/2023 | Exelixis Inc. | — | Food and Beverage | In-kind items and services | $92.24 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| EMBER-4: A RANDOMIZED OPEN-LABEL PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+ HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE | Eli Lilly and Company | $653.45 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 660 | 3,181 | $474,258 | $146,018 |
| 2022 | 17 | 843 | 7,437 | $708,420 | $254,252 |
| 2021 | 23 | 1,014 | 10,887 | $832,197 | $320,297 |
| 2020 | 22 | 1,069 | 22,564 | $1.8M | $710,633 |
Total Patients
3,586
Total Services
44,069
Medicare Billing
$1.4M
Procedure Codes
87
All Medicare Procedures & Services
87 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 170 | 434 | $123,835 | $35,692 | 28.8% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 14 | 1,920 | $71,100 | $34,914 | 49.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 159 | 319 | $90,328 | $22,281 | 24.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 89 | 118 | $47,340 | $12,991 | 27.4% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 19 | 108 | $41,256 | $10,797 | 26.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 61 | 88 | $35,265 | $10,218 | 29.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 37 | 37 | $18,685 | $5,460 | 29.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 37 | 37 | $18,469 | $5,005 | 27.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 22 | 24 | $12,000 | $3,261 | 27.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 18 | 52 | $9,360 | $3,222 | 34.4% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 18 | 21 | $5,355 | $1,957 | 36.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 16 | 23 | $1,265 | $220.60 | 17.4% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 24 | 4,260 | $149,100 | $72,858 | 48.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 226 | 796 | $217,150 | $65,595 | 30.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 156 | 374 | $101,213 | $26,976 | 26.7% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 27 | 172 | $65,704 | $18,241 | 27.8% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2022 | 34 | 98 | $15,680 | $15,645 | 99.8% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Facility | 2022 | 23 | 74 | $11,840 | $11,818 | 99.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 46 | 73 | $27,040 | $9,028 | 33.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 52 | 65 | $24,108 | $6,757 | 28.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 25 | 69 | $17,595 | $5,529 | 31.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 37 | 37 | $18,685 | $5,425 | 29.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 23 | 23 | $11,500 | $3,570 | 31.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 26 | 26 | $13,130 | $3,523 | 26.8% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2022 | 19 | 212 | $11,448 | $2,632 | 23.0% |
About Dr. Sam Benjamin, M.D
Dr. Sam Benjamin, M.D is a Medical Oncology healthcare provider based in Syracuse, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/19/2008. The National Provider Identifier (NPI) number assigned to this provider is 1437316304.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sam Benjamin, M.D has received a total of $8,717 in payments from pharmaceutical and medical device companies, with $346.56 received in 2024. These payments were reported across 47 transactions from 18 companies. The most common payment nature is "Consulting Fee" ($4,365).
As a Medicare-enrolled provider, Benjamin has provided services to 3,586 Medicare beneficiaries, totaling 44,069 services with total Medicare billing of $1.4M. Data is available for 4 years (2020–2023), covering 87 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Syracuse, NY
- Active Since 05/19/2008
- Last Updated 08/22/2013
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1437316304
Products in Payments
- Enhertu (Drug) $5,009
- FOTIVDA (Drug) $160.98
- Lenvima (Drug) $124.69
- KEYTRUDA (Biological) $102.62
- FRUZAQLA (Drug) $47.91
- CABOMETYX (Drug) $38.95
- ERLEADA (Drug) $36.36
- Blincyto (Biological) $26.79
- Zoladex (Drug) $24.01
- ILLUCCIX (Drug) $22.91
- DARZALEX (Biological) $22.47
- PADCEV (Biological) $21.37
- IMFINZI (Biological) $21.30
- TAGRISSO (Drug) $18.90
- Xtandi (Drug) $18.09
- Xermelo (Drug) $17.50
- KISQALI (Drug) $17.44
- KRAZATI (Drug) $17.04
- INLYTA (Drug) $15.20
- BOSULIF (Drug) $9.26
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Syracuse
Haider Khadim, Md, MD
Medical Oncology — Payments: $52,887
Medical Oncology $52,887
Dr. Simrit Walia, M.d, M.D
Medical Oncology — Payments: $7,061
Medical Oncology $7,061
Dr. Alina Basnet, Md, MD
Medical Oncology — Payments: $1,689
Medical Oncology $1,689
Dr. Gloria Morris, Md, MD
Medical Oncology — Payments: $11.92
Medical Oncology $11.92